Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Multiple Sclerosis (MS) is an autoimmune inflammatory disease that presents clinically with a range of symptoms including motor, sensory, and cognitive dysfunction as well as demyelination and lesion formation in brain and spinal cord. A variety of animal models of MS have been developed that share many of the pathological hallmarks of MS including motor deficits (ascending paralysis), demyelination and axonal damage of central nervous system (CNS) tissue. In recent years, neuropathic pain has been recognized as a prevalent symptom of MS in a majority of patients. To date, there have been very few investigations into sensory disturbances in animal models of MS. The current work contains the first assessment of hind paw mechanical allodynia (von Frey test) over the course of a relapsing-remitting myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (MOG-EAE) rat model of MS and establishes the utility of this model in examining autoimmune induced sensory dysfunction. We demonstrate periods of both decreased responsiveness to touch that precedes the onset of hind limb paralysis, and increased responsiveness (allodynia) that occurs during the period of motor deficit amelioration traditionally referred to as symptom remission. Furthermore, we tested the ability of our recently characterized anti-inflammatory IL-10 gene therapy to treat the autoimmune inflammation induced behavioral symptoms and tissue histopathological changes. This therapy is shown here to reverse inflammation induced paralysis, to reduce disease associated reduction in sensitivity to touch, to prevent the onset of allodynia, to reverse disease associated loss of body weight, and to suppress CNS glial activation associated with disease progression in this model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529
How common are the "common" neurologic disorders?
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007) · Neurology · doi:10.1212/01.wnl.0000252807.38124.a3 · Cited by 1,365 · cited 1×
“Multiple Sclerosis (MS) is an autoimmune disease affecting at least 1 in 1000 people in the US and is anticipated to become substantially more prevalent in coming years (Hirtz et al., 2007).”
BackgroundMICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984
Viviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Cunningham, A. J., Murray, C. A., O'Neill, L. A. J., Lynch, M. A., & O'Connor, J. J. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12252-4 · Cited by 433 · cited 1×
“These inflammatory molecules may profoundly change signaling properties of neurons (Katsuki et al., 1990; Cunningham et al., 1996; Viviani et al., 2003) and lead to demyelination and axonal loss, two hallmarks of MS (Bruck, 2005; Hendriks et al., 2005).”
BackgroundChemotherapy-evoked Painful Peripheral Neuropathy
Polomano, R. C., & Bennett, G. J. (2001) · Pain Medicine · doi:10.1046/j.1526-4637.2001.002001008.x · Cited by 100
Cited by
Pathological pain and the neuroimmune interface
Grace, P. M., Hutchinson, M. R., Maier, S. F., & Watkins, L. R. (2014) · Nature Reviews Immunology · doi:10.1038/nri3621 · Cited by 932
Self-citationThe role of the immune system in the generation of neuropathic pain
Calvo, M., Dawes, J. M., & Bennett, D. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70134-5 · Cited by 445
Watkins, L. R., Hutchinson, M. R., Rice, K. C., & Maier, S. F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.002 · Cited by 438
Self-citationImmune modulation by curcumin: The role of interleukin-10
Mollazadeh, H., Cicero, A. F. G., Blesso, C. N., Pirro, M., Majeed, M., & Sahebkar, A. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1358139 · Cited by 381
Regulatory T cells in multiple sclerosis and myasthenia gravis
Danikowski, K. M., Jayaraman, S., & Prabhakar, B. S. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0892-8 · Cited by 323
Metadata
- Authors
- Sloane, E., Ledeboer, A., Seibert, W., Coats, B., van Strien, M., Maier, S. F., Johnson, K. W., Chavez, R., Watkins, L. R., Leinwand, L., Milligan, E. D., & Van Dam, A. M.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 23
- Issue
- 1
- Pages
- 92-100
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W2012860078
- Cited by
- 105
- References
- 6
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. https://app.cochat.ai/papers/10.1016/j.bbi.2008.09.004
- The paper
- Sloane, E., Ledeboer, A., Seibert, W., Coats, B., van Strien, M., Maier, S. F., Johnson, K. W., Chavez, R., Watkins, L. R., Leinwand, L., Milligan, E. D., & Van Dam, A. M. (2009). Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2008.09.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.